![](/img/cover-not-exists.png)
1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types
Zhao, X, Shen, J, Gopalakrishnan, M, Feng, Y, Schmidt, B J, Statkevich, P, Kelleher, T, Rashford, M, Ivaturi, V, Gobburu, J V S, Agrawal, S, Bello, A, Roy, AVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy288.103
Date:
October, 2018
File:
PDF, 78 KB
2018